Online inquiry

IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15036MR)

This product GTTS-WQ15036MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD47 gene. The antibody can be applied in Cancers, Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001777.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 961
UniProt ID Q08722
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15036MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ162MR IVTScrip™ mRNA-Anti-EGFR, 1-26/3-67(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 1-26/3-67
GTTS-WQ10192MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, LDP-02(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA LDP-02
GTTS-WQ6907MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ENB-0040
GTTS-WQ4883MR IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BYM338
GTTS-WQ7727MR IVTScrip™ mRNA-Anti-GLP1R, GLP-1Fc(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA GLP-1Fc
GTTS-WQ3376MR IVTScrip™ mRNA-Anti-Canlupfam CD52, AT-005(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AT-005
GTTS-WQ12197MR IVTScrip™ mRNA-Anti-CSF2, MORAb-022(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MORAb-022
GTTS-WQ12827MR IVTScrip™ mRNA-Anti-FZD10, ONC-005(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ONC-005
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW